Gain Therapeutics Inc. (NASDAQ: GANX) received approval from Australian ethics committees to extend dosing in its Phase 1b clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE